# CNS Biomarkers

*Report generated: 2026-01-29 16:01:40*

**10 papers** | **3 trials**

---

## Papers

### 1. Overnight Dynamics of Ventricular Cerebrospinal Fluid Amyloid-Beta, Lactate and Hypocretin in Patients With Hydrocephalus: A Pilot Study.

**Authors:** Casper Schwartz Riedel, Joachim Birch Milan, Niklas Rye Jørgensen, Poul Jennum, Marianne Juhler

**Source:** pubmed | **Published:** 2026-Jan-29

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41607364/](https://pubmed.ncbi.nlm.nih.gov/41607364/)

*Summary not available.*

### 2. Clustering Algorithm Reveals Dopamine-Motor Mismatch in Cognitively Preserved Parkinson's Disease.

**Authors:** Rachele Malito, Chiara Meneghini, Alice Galli, Luca Gallo, Pierfrancesco Mitrotti et al.

**Source:** pubmed | **Published:** 2026-Jan-28

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41607052/](https://pubmed.ncbi.nlm.nih.gov/41607052/)

*Summary not available.*

### 3. Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.

**Authors:** Roxane Dilcher, Charles B Malpas, Stuart J McDonald, William T O'Brien, Craig Despott et al.

**Source:** pubmed | **Published:** 2026-Jan-28

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41606704/](https://pubmed.ncbi.nlm.nih.gov/41606704/)

*Summary not available.*

### 4. Medial temporal lobe atrophy is associated with age and pathologies, especially small vessel disease.

**Authors:** Danielle van Westen, Erik Stomrud, Luigi Lorenzini, Sebastian Palmqvist, Frederik Barkhof et al.

**Source:** pubmed | **Published:** 2026-Jan-29

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41605967/](https://pubmed.ncbi.nlm.nih.gov/41605967/)

*Summary not available.*

### 5. Electron Transfer Mechanism-Mediated Host-Guest Nanoswitch Powered Amplification-Free CRISPR/Cas12a-Electrochemiluminescence Bioassay for Alzheimer's Disease Diagnosis.

**Authors:** Juan Li, Xiaoli Chen, Yu Yang, Yunzhong Xu, Mingchun Lai et al.

**Source:** pubmed | **Published:** 2026-Jan-28

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41605509/](https://pubmed.ncbi.nlm.nih.gov/41605509/)

*Summary not available.*

### 6. Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages.

**Authors:** Nisha Rani, Abhay Moghekar, Daniel D Callow, Kylie H Alm, Corinne Pettigrew et al.

**Source:** pubmed | **Published:** 2026-Feb-24

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41604611/](https://pubmed.ncbi.nlm.nih.gov/41604611/)

*Summary not available.*

### 7. Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.

**Authors:** Rakesh Kumar, Stephanie Gravett, Vesna Jelic, Johannes Lange, Linn Oftedal et al.

**Source:** pubmed | **Published:** 2026-Feb-24

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41604609/](https://pubmed.ncbi.nlm.nih.gov/41604609/)

*Summary not available.*

### 8. In situ NMR and integrative proteomics reveal the interaction signature of serum α-synuclein.

**Authors:** Jinfeng Huang, Rashik Ahmed, Madoka Akimoto, José Carlos Bozelli, Richard M Epand et al.

**Source:** pubmed | **Published:** 2026-Feb-03

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41604267/](https://pubmed.ncbi.nlm.nih.gov/41604267/)

*Summary not available.*

### 9. The preclinical discovery and development of edaravone for the treatment of amyotrophic lateral sclerosis: what lessons have we learnt?

**Authors:** Tifenn Charbonnel, Elodie Richard, Adrien Dupuis, Maelys Palla, Patrick Vourc'h et al.

**Source:** pubmed | **Published:** 2026-Jan-29

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41569095/](https://pubmed.ncbi.nlm.nih.gov/41569095/)

*Summary not available.*

### 10. Label-Free SERS Sensing of Native Aβ with Aptamer-Modified Mesoporous Gold and Gold-Coated Magnetic Nanoparticles Using a Clinical Cohort.

**Authors:** Abubakkar Khan, Jiawei Shen, Aiman Zahid, Cancan Hu, Xuhua Xu et al.

**Source:** pubmed | **Published:** 2026-Jan-28

**Link:** [https://pubmed.ncbi.nlm.nih.gov/41437786/](https://pubmed.ncbi.nlm.nih.gov/41437786/)

*Summary not available.*

## Clinical Trials

### 1. [LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome](https://clinicaltrials.gov/study/NCT07234695)

**NCT ID:** NCT07234695 | **Phase:** Phase 3 | **Status:** RECRUITING

**Conditions:** Down Syndrome, Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Dementia, Alzheimer Dementia (AD), Alzheimer Disease, Alzheimer Disease (AD), Alzheimer Blood Biomarkers, Epilepsy, Seizures

**Interventions:** Levetiracetam 500mg, Placebo

**Sponsor:** Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | **Collaborators:** Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, Hospital Universitario Marqués de Valdecilla, Fundación CITA Alzheimer, University Hospital Virgen de las Nieves

> The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease.

Patients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo.

Both groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.

### 2. [Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain](https://clinicaltrials.gov/study/NCT06797817)

**NCT ID:** NCT06797817 | **Phase:** Phase 3 | **Status:** NOT_YET_RECRUITING

**Conditions:** Alzheimer Disease (AD)

**Interventions:** tributyrin, Placebo

**Sponsor:** Universidad de Almeria

> The goal of this clinical trial is to learn if tributyrin can help prevent or mitigate cognitive decline in individuals with mild Alzheimer's disease (AD). The trial will also examine the safety and effects of tributyrin on inflammation and gut microbiota. The main questions it aims to answer are:

Does tributyrin reduce inflammation and neurodegeneration markers? How does tributyrin affect gut microbiota and intestinal permeability? Researchers will compare tributyrin to a placebo (a look-alike substance that contains no active ingredient) to evaluate its effectiveness.

Participants will:

T...

### 3. [Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)](https://clinicaltrials.gov/study/NCT06182085)

**NCT ID:** NCT06182085 | **Phase:** Phase 2 | **Status:** ACTIVE_NOT_RECRUITING

**Conditions:** Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset

**Interventions:** PRI-002, Placebo

**Sponsor:** PRInnovation GmbH | **Collaborators:** Priavoid, Federal Agency for Disruptive Innovation - SPRIN-D, Julius Clinical

> Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour. The company PRInnovation is developing a new treatment for Alzheimer's disease, called PRI-002. It is thought that PRI-002 can cut the sticked substances back into small pieces. That would reduce the effects of Alzheimer's disease. In the current study the investigators examine whether PRI-002 is safe and effective in participants with mild cognitive impairment (MCI) or mild dementia due to AD.
